Moving from 1.7mg to 2.4mg Wegovy: what actually changes

The myth: 2.4mg is just more of the same

A common assumption is that each dose increase on Wegovy is simply a larger helping of the same effect. The thinking goes: more drug, proportionally more appetite suppression, proportionally more nausea. That picture is incomplete.

Semaglutide is a GLP-1 receptor agonist that works by mimicking a hormone released after eating. It slows gastric emptying, reduces appetite signals in the brain, and influences how the body handles blood sugar. The lower doses in the titration schedule (0.25mg, 0.5mg, 1.0mg, 1.7mg) are primarily there to let your system adapt gradually, rather than to deliver the medicine's full therapeutic effect, and you can find out more about the penultimate step on our wegovy 1.7 mg page. The 2.4mg maintenance dose is where the clinical evidence sits; it's the target the STEP 1 trial was built around.

What that means in practice is that the step from 1.7mg to 2.4mg is different in kind, not just magnitude. Some people notice a clearer shift in appetite and food noise at 2.4mg than they did moving between earlier rungs. Others notice very little change at all. Both experiences are normal. The NHS medicines page on semaglutide notes that gastrointestinal effects are the most common side effects and tend to ease as treatment continues.

What staying at 1.7mg for four or more weeks is actually doing

The minimum time spent at each dose is roughly four weeks, but that figure is a floor, not a ceiling. If 1.7mg is producing significant nausea, disrupted sleep, or persistent vomiting, a prescriber may advise staying longer before stepping up. This is not a failure or a delay, it's the titration schedule working as designed.

There's also a practical timing reality worth naming: if your next pen is due around a bank holiday or you've ordered at the end of the month, the clinical review before a dose increase should happen before the next pen is dispatched, not retrospectively. At nume, every repeat order is reviewed by a prescriber before dispatch, which means the 1.7mg-to-2.4mg step gets proper clinical attention rather than happening automatically. You can read more about how the full Wegovy dose schedule is structured, including why the earlier steps exist.

People sometimes ask whether it's fine to move to 2.4mg ahead of schedule if they're tolerating 1.7mg well. The short answer is that the prescriber makes that call, informed by your weight progress, your side-effect history, and your overall health picture. Rushing the titration doesn't improve outcomes and can increase the likelihood of side effects that force a step back down.

What the 2.4mg dose is associated with in clinical evidence

The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity or overweight plus a weight-related condition for 68 weeks. At 2.4mg semaglutide, average weight loss was around 15% of starting body weight (roughly 15kg for someone starting at 100kg) alongside lifestyle support. That figure represents the full titration course, not a result that appears the moment someone reaches 2.4mg.

For context on how that compares with other medicines in this class, it's worth understanding how 1.7mg and 2.4mg differ before the step-up. Some people see meaningful additional progress after reaching 2.4mg; others find that much of their weight change came earlier in the course.

If less than 5% weight loss has occurred after six months at the maintenance dose, NICE guidance on semaglutide (TA875) recommends that continuing treatment is reviewed. That review is a clinical conversation, not an automatic stop.

Side effects at 2.4mg: what to expect and when to act

Nausea, loose stools, constipation, burping and a general drop in appetite are the most commonly reported effects after a dose increase, including the 1.7mg-to-2.4mg step. For most people these ease within one to two weeks. Eating smaller portions, avoiding fatty or rich meals, and staying well hydrated all help the adjustment period.

Three situations warrant prompt medical attention. First, severe stomach pain that radiates to the back, this can be a sign of pancreatitis, a known but uncommon risk with GLP-1 medicines flagged in a 2026 MHRA Drug Safety Update. Second, signs of significant dehydration from persistent vomiting or diarrhoea. Third, symptoms of an allergic reaction such as swelling, difficulty breathing, or a rash.

If you have any concerns about a side effect after moving to 2.4mg, the right first step is your prescriber, not reducing the dose on your own initiative. Taking an incorrect dose carries its own risks, there's a useful resource on what to do if a Wegovy dose goes wrong if you need it. And if you're still weighing up whether this treatment is the right fit for your situation, checking your eligibility with our team is a good place to begin.